MRTX849 Shows Clinical Activity in KRAS G12C-Mutant Cancers

A compound called MRTX849 is showing signs of being the first effective inhibitor of the KRAS G12C-mutant subtype of non-small cell lung and colorectal cancers.

Source: CancerNetwork - November 1, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news